CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing
P García-Roca, M Medeiros, H Reyes… - Archives of medical …, 2012 - Elsevier
BACKGROUND AND AIMS: Variability in CYP3A5 expression associated with differences in
tacrolimus bioavailability has been documented. The wild-type allele CYP3A5* 1 expresses …
tacrolimus bioavailability has been documented. The wild-type allele CYP3A5* 1 expresses …
Evaluation of pharmacogenetics of drug-metabolizing enzymes and drug efflux transporter in renal transplants receiving immunosuppressants
K Sridharan, S Shah, A Jassim, M Hammad… - Journal of Personalized …, 2022 - mdpi.com
Cytochrome P450 (CYP) enzymes, such as CYP3A4, and CYP3A5, P450 oxidoreductase
(POR), peroxisome proliferator activated receptor alpha (PPAR-alpha), and drug transporter …
(POR), peroxisome proliferator activated receptor alpha (PPAR-alpha), and drug transporter …
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
DA Hesselink, RHN van Schaik… - Pharmacogenetics …, 2008 - journals.lww.com
Objective Patients expressing the tacrolimus-metabolizing enzyme, cytochrome P450 (CYP)
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …
3A5, require more tacrolimus to reach target concentrations. We studied the influence of the …
Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus
H Bruckmueller, AN Werk, L Renders… - Therapeutic drug …, 2015 - journals.lww.com
Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …
[PDF][PDF] Association between CYP3A5 genetic polymorphisms with tacrolimus dose requirement and allograft outcomes in Iranian kidney transplant recipients
S Ghafari, S Dashti-Khavidaki… - Iranian Journal of …, 2019 - researchgate.net
Methods. In this prospective study, 110 adult kidney transplant recipients treated with
tacrolimus were genotyped for the presence of common SNPs: rs776746: A> G (CYP3A5 …
tacrolimus were genotyped for the presence of common SNPs: rs776746: A> G (CYP3A5 …
Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients
P Chen, J Li, J Li, R Deng, Q Fu, J Chen… - Journal of Clinical …, 2017 - Wiley Online Library
What is known and objective Tacrolimus is a widely used immunosuppressive drug with
marked pharmacokinetic variability partly due to CYP 3A5 polymorphism. Our study aimed to …
marked pharmacokinetic variability partly due to CYP 3A5 polymorphism. Our study aimed to …
[HTML][HTML] Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients—Preliminary Report
K Warzyszyńska, M Zawistowski, E Karpeta… - Transplantation …, 2022 - Elsevier
Background Previous reports have established that patient CYP3A5 allelic variability may be
the most important genetic contributor to interindividual variation in tacrolimus exposure in …
the most important genetic contributor to interindividual variation in tacrolimus exposure in …
Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients
J Mendes, A Martinho, O Simoes, A Mota… - Transplantation …, 2009 - Elsevier
Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine (CsA), play an
essential role in graft survival, preventing rejection. Large interindividual differences in drug …
essential role in graft survival, preventing rejection. Large interindividual differences in drug …
Impact of CYP 3A5 genomic variances on clinical outcomes among African American kidney transplant recipients
TE Asempa, LM Rebellato, S Hudson… - Clinical …, 2018 - Wiley Online Library
Little is known about the impact of CYP 3A5 polymorphisms on transplantation outcomes
among African American (AA) kidney transplant recipients (KTRs). To assess this issue …
among African American (AA) kidney transplant recipients (KTRs). To assess this issue …
Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre
Y Cheng, H Li, Y Meng, H Liu, L Yang… - … Journal of Clinical …, 2015 - Wiley Online Library
Aim As a substrate of cytochrome P450 (CYP) 3A5, tacrolimus is characterised by a narrow
therapeutic index and large inter‐individual variability. Our objective was to determine the …
therapeutic index and large inter‐individual variability. Our objective was to determine the …